Download MendeleyLigandability Assessment of IL-1 beta by Integrated Hit Identification Approaches.
Vulpetti, A., Rondeau, J.M., Bellance, M.H., Blank, J., Boesch, R., Boettcher, A., Bornancin, F., Buhr, S., Connor, L.E., Dumelin, C.E., Esser, O., Hediger, M., Hintermann, S., Hommel, U., Koch, E., Lapointe, G., Leder, L., Lehmann, S., Lehr, P., Meier, P., Muller, L., Ostermeier, D., Ramage, P., Schiebel-Haddad, S., Smith, A.B., Stojanovic, A., Velcicky, J., Yamamoto, R., Hurth, K.(2024) J Med Chem
- PubMed: 38728572
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00240
- Primary Citation of Related Structures:
8RYK, 8RYS, 8RZB - PubMed Abstract:
Human interleukin-1β (IL-1β) is a pro-inflammatory cytokine that plays a critical role in the regulation of the immune response and the development of various inflammatory diseases. In this publication, we disclose our efforts toward the discovery of IL-1β binders that interfere with IL-1β signaling. To this end, several technologies were used in parallel, including fragment-based screening (FBS), DNA-encoded library (DEL) technology, peptide discovery platform (PDP), and virtual screening. The utilization of distinct technologies resulted in the identification of new chemical entities exploiting three different sites on IL-1β, all of them also inhibiting the interaction with the IL-1R1 receptor. Moreover, we identified lysine 103 of IL-1β as a target residue suitable for the development of covalent, low-molecular-weight IL-1β antagonists.
Organizational Affiliation:
Biomedical Research, Novartis, CH-4002 Basel, Switzerland.
